You are here: Home » Companies » News
Business Standard

Made-in-India drugs to be in dock at Capitol Hill

"India is the most important in terms of volume of imports, so is becoming the main focus"

Sushmi Dey  |  New Delhi 

The concerns surrounding drug manufacturing practices in India appear to have reached foreign shores, beyond the international regulators’ domain. whistle-blower Dinesh Thakur, along with a group of medical academicians and researchers, is set to address the US Congressional staff (of American legislators) on Wednesday at an event at in Washington. The group is expected to raise issues about the quality of available in the US, primarily those imported from India.

Apart from Thakur, the panellists for the much-hyped event include Amir Attaran, a professor of law and medicine at the University of Ottawa, Harry Lever, a senior cardiologist at the Cleveland Clinic and Preston Mason, a member of the cardiovascular division at Brigham and Women’s Hospital and Harvard Medical School. The event will be moderated by Roger Bate, an expert on substandard and falsified


ALSO READ: Ranbaxy puts API supplies on hold

“Our aim is primarily educational, to explain there is a problem with some medicines, both domestically but more noticeably from imports from emerging markets — India is the most important in terms of volume of imports, so is becoming the main focus,” Bate told Business Standard, explaining the agenda of the event.

In the wake of US Food and Drug Administration (FDA) commissioner Margaret Hamburg’s recent India visit, Thakur, Bate and Attaran have also published a working paper titled ‘India’s drug quality under the spotlight with FDA’. The working paper assumes significance as it has highlighted some key areas and concerns related to drug safety, regulatory mechanism in India as well as in the US and also the statement of intent signed between the American and Indian regulator during Hamburg’s recent visit to India, enabling the Indian regulators to accompany US authorities during their inspections of facilities here as well as prior information about such activities.

ALSO READ: Not targeting Ranbaxy or Indian companies: US FDA

These issues are also likely to be discussed with Congressional staff during the meeting at

Blaming Indian government for politicising FDA regulatory actions, the working paper said the government should “realise that its entire regulatory structures are a mess, and political tit for tats will do nothing to improve matters”.

Referring to Controller General of India (DCGI) G N Singh’s recent statement that the Indian regulator was mulling inspection of foreign facilities that supply to India, the paper said the regulator was making a “blatant political statement”, as it does not have enough resources.

ALSO READ: Ranbaxy Paonta Sahib may have seen 6-10 exits, say sources

Raising questions over the integrity of the Indian regulatory system, the trio pointed to concerns on the intended regulatory collaboration between Indian and America. “…the FDA has to realise that it is engaging with a highly politicised organisation that does the bidding of powerful interests in the Indian industry and where a culture of sensible even-handed regulation does not exist,” the working paper said.

However, many in India feel the event as well as the paper is motivated with an idea to “malign the Indian drug manufacturing industry”, which is spreading its wings worldwide and is posing a potential threat to multinational pharmaceutical companies, mainly in the US.

ALSO READ: Hamburg set to wrap up India trip on tough note

Of late, some of Indian manufacturing facilities of leading pharmaceutical such as and have come under the FDA scanner for violating good manufacturing practices. The problems highlighted by the American regulator during its enforcements on these were mostly pertaining to manufacturing processes, data integrity and hygienic issues.

The event at is being watched by many as it has the potential to add to troubles of Indian manufacturing industry, which is already struggling with a trust deficit world over following latest enforcements by FDA.

India, known as the ‘pharmacy of the developing world’, is one of the major low-cost drug suppliers to developed as well as emerging markets. With about 200 FDA factories, India is the largest exporter of to the US, the world’s largest pharmaceutical market.

RECOMMENDED FOR YOU

Made-in-India drugs to be in dock at Capitol Hill

"India is the most important in terms of volume of imports, so is becoming the main focus"

"India is the most important in terms of volume of imports, so is becoming the main focus" The concerns surrounding drug manufacturing practices in India appear to have reached foreign shores, beyond the international regulators’ domain. whistle-blower Dinesh Thakur, along with a group of medical academicians and researchers, is set to address the US Congressional staff (of American legislators) on Wednesday at an event at in Washington. The group is expected to raise issues about the quality of available in the US, primarily those imported from India.

Apart from Thakur, the panellists for the much-hyped event include Amir Attaran, a professor of law and medicine at the University of Ottawa, Harry Lever, a senior cardiologist at the Cleveland Clinic and Preston Mason, a member of the cardiovascular division at Brigham and Women’s Hospital and Harvard Medical School. The event will be moderated by Roger Bate, an expert on substandard and falsified

ALSO READ: Ranbaxy puts API supplies on hold

“Our aim is primarily educational, to explain there is a problem with some medicines, both domestically but more noticeably from imports from emerging markets — India is the most important in terms of volume of imports, so is becoming the main focus,” Bate told Business Standard, explaining the agenda of the event.

In the wake of US Food and Drug Administration (FDA) commissioner Margaret Hamburg’s recent India visit, Thakur, Bate and Attaran have also published a working paper titled ‘India’s drug quality under the spotlight with FDA’. The working paper assumes significance as it has highlighted some key areas and concerns related to drug safety, regulatory mechanism in India as well as in the US and also the statement of intent signed between the American and Indian regulator during Hamburg’s recent visit to India, enabling the Indian regulators to accompany US authorities during their inspections of facilities here as well as prior information about such activities.

ALSO READ: Not targeting Ranbaxy or Indian companies: US FDA

These issues are also likely to be discussed with Congressional staff during the meeting at

Blaming Indian government for politicising FDA regulatory actions, the working paper said the government should “realise that its entire regulatory structures are a mess, and political tit for tats will do nothing to improve matters”.

Referring to Controller General of India (DCGI) G N Singh’s recent statement that the Indian regulator was mulling inspection of foreign facilities that supply to India, the paper said the regulator was making a “blatant political statement”, as it does not have enough resources.

ALSO READ: Ranbaxy Paonta Sahib may have seen 6-10 exits, say sources

Raising questions over the integrity of the Indian regulatory system, the trio pointed to concerns on the intended regulatory collaboration between Indian and America. “…the FDA has to realise that it is engaging with a highly politicised organisation that does the bidding of powerful interests in the Indian industry and where a culture of sensible even-handed regulation does not exist,” the working paper said.

However, many in India feel the event as well as the paper is motivated with an idea to “malign the Indian drug manufacturing industry”, which is spreading its wings worldwide and is posing a potential threat to multinational pharmaceutical companies, mainly in the US.

ALSO READ: Hamburg set to wrap up India trip on tough note

Of late, some of Indian manufacturing facilities of leading pharmaceutical such as and have come under the FDA scanner for violating good manufacturing practices. The problems highlighted by the American regulator during its enforcements on these were mostly pertaining to manufacturing processes, data integrity and hygienic issues.

The event at is being watched by many as it has the potential to add to troubles of Indian manufacturing industry, which is already struggling with a trust deficit world over following latest enforcements by FDA.

India, known as the ‘pharmacy of the developing world’, is one of the major low-cost drug suppliers to developed as well as emerging markets. With about 200 FDA factories, India is the largest exporter of to the US, the world’s largest pharmaceutical market.

image
Business Standard
177 22

Made-in-India drugs to be in dock at Capitol Hill

"India is the most important in terms of volume of imports, so is becoming the main focus"

The concerns surrounding drug manufacturing practices in India appear to have reached foreign shores, beyond the international regulators’ domain. whistle-blower Dinesh Thakur, along with a group of medical academicians and researchers, is set to address the US Congressional staff (of American legislators) on Wednesday at an event at in Washington. The group is expected to raise issues about the quality of available in the US, primarily those imported from India.

Apart from Thakur, the panellists for the much-hyped event include Amir Attaran, a professor of law and medicine at the University of Ottawa, Harry Lever, a senior cardiologist at the Cleveland Clinic and Preston Mason, a member of the cardiovascular division at Brigham and Women’s Hospital and Harvard Medical School. The event will be moderated by Roger Bate, an expert on substandard and falsified

ALSO READ: Ranbaxy puts API supplies on hold

“Our aim is primarily educational, to explain there is a problem with some medicines, both domestically but more noticeably from imports from emerging markets — India is the most important in terms of volume of imports, so is becoming the main focus,” Bate told Business Standard, explaining the agenda of the event.

In the wake of US Food and Drug Administration (FDA) commissioner Margaret Hamburg’s recent India visit, Thakur, Bate and Attaran have also published a working paper titled ‘India’s drug quality under the spotlight with FDA’. The working paper assumes significance as it has highlighted some key areas and concerns related to drug safety, regulatory mechanism in India as well as in the US and also the statement of intent signed between the American and Indian regulator during Hamburg’s recent visit to India, enabling the Indian regulators to accompany US authorities during their inspections of facilities here as well as prior information about such activities.

ALSO READ: Not targeting Ranbaxy or Indian companies: US FDA

These issues are also likely to be discussed with Congressional staff during the meeting at

Blaming Indian government for politicising FDA regulatory actions, the working paper said the government should “realise that its entire regulatory structures are a mess, and political tit for tats will do nothing to improve matters”.

Referring to Controller General of India (DCGI) G N Singh’s recent statement that the Indian regulator was mulling inspection of foreign facilities that supply to India, the paper said the regulator was making a “blatant political statement”, as it does not have enough resources.

ALSO READ: Ranbaxy Paonta Sahib may have seen 6-10 exits, say sources

Raising questions over the integrity of the Indian regulatory system, the trio pointed to concerns on the intended regulatory collaboration between Indian and America. “…the FDA has to realise that it is engaging with a highly politicised organisation that does the bidding of powerful interests in the Indian industry and where a culture of sensible even-handed regulation does not exist,” the working paper said.

However, many in India feel the event as well as the paper is motivated with an idea to “malign the Indian drug manufacturing industry”, which is spreading its wings worldwide and is posing a potential threat to multinational pharmaceutical companies, mainly in the US.

ALSO READ: Hamburg set to wrap up India trip on tough note

Of late, some of Indian manufacturing facilities of leading pharmaceutical such as and have come under the FDA scanner for violating good manufacturing practices. The problems highlighted by the American regulator during its enforcements on these were mostly pertaining to manufacturing processes, data integrity and hygienic issues.

The event at is being watched by many as it has the potential to add to troubles of Indian manufacturing industry, which is already struggling with a trust deficit world over following latest enforcements by FDA.

India, known as the ‘pharmacy of the developing world’, is one of the major low-cost drug suppliers to developed as well as emerging markets. With about 200 FDA factories, India is the largest exporter of to the US, the world’s largest pharmaceutical market.

image
Business Standard
177 22